Expert Ratings For Catalent
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter:
Morgan Stanley Maintains Overweight on Catalent, Raises Price Target to $160
Morgan Stanley maintains Catalent (NYSE:CTLT) with a Overweight and raises the price target from $147 to $160.
RBC Capital Maintains Outperform on Catalent, Raises Price Target to $155
RBC Capital analyst Sean Dodge maintains Catalent (NYSE:CTLT) with a Outperform and raises the price target from $145 to $155.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Chair And CEO Of Catalent Trades $22M In Company Stock
John Chiminski, Chair And CEO at Catalent (NYSE:CTLT), made a large buy and sell of company shares on October 1, according to a new SEC filing.
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 9)